S-Acetyl Glutathione and Performance Recovery in Soccer
keskiviikko 1. heinäkuuta 2026 päivittänyt: Dimitrios Draganidis, University of Thessaly
Pharmacodynamics & Pharmacokinetics Study of S-Acetyl Glutathione in Highly Trained Soccer Players
Soccer players display elevated inflammatory and oxidative stress markers combined with reduced soccer specific performance over a 72-hour period.
However, in modern soccer, players participate very often in 2 or 3 matches within a week, with a recovery period of 72 hours between successive matches, that is insufficient to restore skeletal muscle homeostasis and performance.
Of note, reduced glutathione (GSH) levels, a tripeptide consisting of the amino acids cysteine, glycine and glutamic acid, are substantially reduced during the 72-hour recovery period after a match because of the trauma-related acute inflammatory and oxidative stress response.
GSH availability is a crucial regulator of cellular redox status, affecting numerous intracellular and physiological processes such as redox signalling, immunoregulation and muscle metabolism.
Indeed, enhanced GSH availability following muscle damaging exercise has been shown to be beneficial for skeletal muscle and performance recovery by mitigating the inflammatory and oxidative stress response.
Thus, the enhancement of GSH availability through dietary interventions would be a promising strategy to accelerate skeletal muscle and performance recovery following a soccer game.
S-Acetyl Glutathione (SAG) is a glutathione precursor with enhanced absorption kinetics due to chemical S-acetylation of the thiol group on the cysteinyl amino acid of GSH and oral administration of SAG has been shown to be more effective in restoring intracellular glutathione levels compared to oral glutathione.
The aim of this study is to (i) perform a pharmacokinetic assessment of 200 mg/day vs 500 mg/day of SAG during a 7-day supplementation period (pre-loading) and (ii) to establish the pharmacodynamic effect of the two dosages at 24, 48 and 72h following a 90-minute official soccer match.
Tutkimuksen yleiskatsaus
Tila
Ei vielä rekrytointia
Ehdot
Yksityiskohtainen kuvaus
Following baseline testing [including assessment of anthropometrics, body composition (via DXA instrumentation) and physical performance (cardiorespiratory fitness, drop jump and countermovement jump performance, repeated sprint anility, isokinetic peak torque)], 20 well-trained, soccer players will participate in three trials, receiving daily (i) 200 mg SAG, (ii) 500 mg SAG or (iii) Placebo, according to a randomized, double-blind, crossover, repeated-measures design. The duration of each trial will be 11 days, including a 7-day pre-loading period (days 1 -7), a match day (day 8) and 3 consecutive recovery days after the match (days 9-11). Between trials a 3-week washout period will be implemented.
Pre-loading period: During the 7-day pre-loading period players will participate daily in training sessions according to a soccer-specific weekly training schedule, while receiving the respective supplement. Blood samples will be collected on day 1 and day 7 while daily nutrient intake (via 7-day diet recalls), physical activity level (via accelerometry) and training load (via global positioning system instrumentation during training sessions) will be monitored daily.
Match day: On match day, players will participate in an official 90-min soccer match. Field activity (total distance, average and maximum speed, high intensity running, high speed running, accelerations, decelerations) and heart rate (mean and maximum heart rate) will be continuously monitored using global positioning system (GPS) and heart rate monitors, respectively.
Recovery days: During the 3-day recovery period after the match, players will participate daily in (i) morning testing sessions and (ii) training sessions in the evening. Testing sessions will include blood sampling and performance measurements including drop jump and countermovement jump performance, repeated sprint anility, isokinetic peak torque and muscle soreness (DOMS). Dietary intake (via a 3-day diet recalls), physical activity level (via accelerometry) and training load (via GPS instrumentation during training sessions) will be monitored daily.
Opintotyyppi
Interventio
Ilmoittautuminen (Arvioitu)
20
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskeluyhteys
- Nimi: Dimitrios Draganidis, PhD
- Puhelinnumero: +30 2431047078
- Sähköposti: ddraganidis@uth.gr
Tutki yhteystietojen varmuuskopiointi
- Nimi: Athanasios Poulios, PhD
- Puhelinnumero: +30 2431047053
- Sähköposti: athanpoul@gmail.com
Opiskelupaikat
-
-
Karies
-
Trikala, Karies, Kreikka, 42100
- Department of Physical Education and Sport Science, University of Thessaly
-
Ottaa yhteyttä:
- Ioannis G Fatouros, PhD
- Puhelinnumero: +30 2431047047
- Sähköposti: ifatouros@uth.gr
-
Ottaa yhteyttä:
- Athanasios Z Jamurtas, PhD
- Puhelinnumero: +30 24310 47054
- Sähköposti: ajamurt@uth.gr
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
Hyväksyy terveitä vapaaehtoisia
Joo
Kuvaus
Inclusion Criteria:
- participation at elite (top three division leagues) for ≥ 4 years
- no recent history of febrile illness, musculoskeletal problems and metabolic diseases
- no consumption of medications and performance-enhancing supplements (including anti-inflammatory, antioxidants, vitamins and multivitamin supplements) for at least 6 months prior to the study
- participation in at least 5 training sessions and 1 match per week
- non-smokers
Exclusion Criteria:
- musculoskeletal injury
- consumption of medication and performance-enhancing supplements
- illness during the course of the study
- loss of follow-up measurements
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Muut
- Jako: Satunnaistettu
- Inventiomalli: Crossover-tehtävä
- Naamiointi: Kolminkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: SAG-200 Trial
Oral administration of S-Acetyl Glutathione (SAG)
|
Participants will be supplemented daily with 200 mg of S-acetyl glutathione, orally, over the 11-day experimental period.
|
|
Kokeellinen: SAG-500 Trial
Oral administration of S-Acetyl Glutathione (SAG)
|
Participants will be supplemented daily with 500 mg of S-acetyl glutathione, orally, over the 11-day experimental period.
|
|
Placebo Comparator: Placebo Trial
Oral administration of placebo
|
Participants will be supplemented daily with placebo, orally, over the 11-day experimental period.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in creatine kinase levels
Aikaikkuna: Day 1, day 7, day 9, day 10 and day 11
|
Creatine kinase concentration will be measured in serum using a Clinical Chemistry Analyzer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in myoglobin levels
Aikaikkuna: Day 1, day 7, day 9, day 10 and day 11
|
Myoglobin concentration will be measured in serum using a Clinical Chemistry Analyzer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in reduced glutathione
Aikaikkuna: Day 1, day 7, day 9, day 10 and day 11
|
Reduced glutathione will be photometrically determined in red blood cell lysates using a spectrophotometer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in oxidized glutathione
Aikaikkuna: Day 1, day 7, day 9, day 10 and day 11
|
Oxidized glutathione will be photometrically determined in red blood cell lysates using a spectrophotometer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in glutathione reductase activity
Aikaikkuna: Day 1, day 7, day 9, day 10 and day 11
|
Glutathione reductase activity will be photometrically determined in red blood cell lysates using a spectrophotometer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in glutathione peroxidase activity
Aikaikkuna: Day 1, day 7, day 9, day 10 and day 11.
|
Glutathione peroxidase activity will be photometrically determined in red blood cell lysates using a spectrophotometer
|
Day 1, day 7, day 9, day 10 and day 11.
|
|
Change in catalase activity
Aikaikkuna: Day 1, day 7, day 9, day 10 and day 11
|
Catalase activity will be photometrically determined in red blood cell lysates using a spectrophotometer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in superoxide dismutase activity
Aikaikkuna: Day 1, day 7, day 9, day 10 and day 11
|
Superoxide dismutase activity will be photometrically determined in red blood cell lysates using a spectrophotometer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in maximal voluntary isometric contraction
Aikaikkuna: Day 1, day 9, day 10 and day 11
|
Maximal voluntary isometric contraction will be assessed at a 60o knee joint angle, in both dominant and non-dominant limb, using an isokinetic dynamometer
|
Day 1, day 9, day 10 and day 11
|
|
Change in maximal peak torque
Aikaikkuna: Day 1, day 9, day 10 and day 11
|
Maximal concentric and eccentric peak torque at 60o/s of the knee extensors and flexors in both dominant and non-dominant limb, will be assessed on an isokinetic dynamometer
|
Day 1, day 9, day 10 and day 11
|
|
Change in jumping performance
Aikaikkuna: Day 1, day 9, day 10 and day11
|
Countermovement jump and drop jump performance will be tested using an optical measurement system consisting of a transmitting and receiving bar
|
Day 1, day 9, day 10 and day11
|
|
Change in repeated sprint ability
Aikaikkuna: Day 1, day 9, day 10 and day 11
|
Repeated sprint ability will be assessed by performing 5x25 m sprints interspersed by a 25-seconds recovery period using infrared photocells
|
Day 1, day 9, day 10 and day 11
|
|
Change in delayed onset muscle soreness (DOMS)
Aikaikkuna: Day 1, day 9, day 10 and day 11
|
DOMS will be assessed using a 10-scale visual analogue scale
|
Day 1, day 9, day 10 and day 11
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in total distance covered
Aikaikkuna: Daily throughout the 11-day experimental period
|
Total distance (km) covered during training and match play will be monitored using Global Positioning System (GPS)
|
Daily throughout the 11-day experimental period
|
|
Change in internal load
Aikaikkuna: Daily throughout the 11-day experimental period
|
Heart rate during training sessions and the match will be monitored using heart rate monitors
|
Daily throughout the 11-day experimental period
|
|
Change in dietary intake
Aikaikkuna: Daily throughout the 11-day experimental period
|
Dietary intake will be assessed using diet recalls
|
Daily throughout the 11-day experimental period
|
|
Change in time spent in moderate-to-vigorous physical activity
Aikaikkuna: Daily throughout the 11-day experimental period
|
The time (minutes) spent in moderate-to-vigorous physical activity on a daily basis will be monitored using accelerometers
|
Daily throughout the 11-day experimental period
|
|
Change in distance covered with high-intensity running
Aikaikkuna: Daily throughout the 11-day experimental period
|
Distance (km) covered with high-intensity running during training and match play will be monitored using Global Positioning System (GPS)
|
Daily throughout the 11-day experimental period
|
|
Change in distance covered with sprinting
Aikaikkuna: Daily throughout the 11-day experimental period
|
Distance (km) covered with high-intensity sprinting during training and match play will be monitored using Global Positioning System (GPS)
|
Daily throughout the 11-day experimental period
|
|
Change in accelerations
Aikaikkuna: Daily throughout the 11-day experimental period
|
The number of accelerations performed during training and match play will be monitored using Global Positioning System (GPS)
|
Daily throughout the 11-day experimental period
|
|
Change in decelerations
Aikaikkuna: Daily throughout the 11-day experimental period
|
The number of decelerations performed during training and match play will be monitored using Global Positioning System (GPS)
|
Daily throughout the 11-day experimental period
|
|
Change in total step count
Aikaikkuna: Daily throughout the 11-day experimental period
|
The total number of steps performed daily will be monitored using accelerometers
|
Daily throughout the 11-day experimental period
|
|
Change in physical activity-related energy expenditure
Aikaikkuna: Daily throughout the 11-day experimental period
|
Energy expenditure (kcal) related to habitual physical activity will be assessed using accelerometers
|
Daily throughout the 11-day experimental period
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Yhteistyökumppanit
Tutkijat
- Päätutkija: Dimitrios Draganidis, PhD, University of Thessaly, Department of Physical Education and Sport Science
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Tiistai 1. syyskuuta 2026
Ensisijainen valmistuminen (Arvioitu)
Sunnuntai 20. joulukuuta 2026
Opintojen valmistuminen (Arvioitu)
Keskiviikko 20. tammikuuta 2027
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Tiistai 9. kesäkuuta 2026
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Keskiviikko 1. heinäkuuta 2026
Ensimmäinen Lähetetty (Todellinen)
Keskiviikko 8. heinäkuuta 2026
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Keskiviikko 8. heinäkuuta 2026
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Keskiviikko 1. heinäkuuta 2026
Viimeksi vahvistettu
Perjantai 1. toukokuuta 2026
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muut tutkimustunnusnumerot
- UTH-06/13.02.2026
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
EI
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Ei
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .